The effects of kisspeptin on β‐cell function, serum metabolites and appetite in humans
-
- Chioma Izzi‐Engbeaya
- Section of Endocrinology and Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine Imperial College London London UK
-
- Alexander N. Comninos
- Section of Endocrinology and Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine Imperial College London London UK
-
- Sophie A. Clarke
- Section of Endocrinology and Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine Imperial College London London UK
-
- Anne Jomard
- Section of Endocrinology and Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine Imperial College London London UK
-
- Lisa Yang
- Section of Endocrinology and Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine Imperial College London London UK
-
- Sophie Jones
- Section of Endocrinology and Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine Imperial College London London UK
-
- Ali Abbara
- Section of Endocrinology and Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine Imperial College London London UK
-
- Shakunthala Narayanaswamy
- Section of Endocrinology and Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine Imperial College London London UK
-
- Pei Chia Eng
- Section of Endocrinology and Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine Imperial College London London UK
-
- Deborah Papadopoulou
- Section of Endocrinology and Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine Imperial College London London UK
-
- Julia K. Prague
- Section of Endocrinology and Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine Imperial College London London UK
-
- Paul Bech
- Section of Endocrinology and Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine Imperial College London London UK
-
- Ian F. Godsland
- Section of Metabolic Medicine, Department of Medicine, Imperial College London St Mary's Hospital London UK
-
- Paul Bassett
- Statsconsultancy Ltd Amersham UK
-
- Caroline Sands
- The MRC‐NIHR National Phenome Centre and Imperial BRC Clinical Phenotyping Centre, Division of Computational, Systems and Digestive Medicine, Department of Surgery and Cancer London UK
-
- Stephane Camuzeaux
- The MRC‐NIHR National Phenome Centre and Imperial BRC Clinical Phenotyping Centre, Division of Computational, Systems and Digestive Medicine, Department of Surgery and Cancer London UK
-
- Maria Gomez‐Romero
- The MRC‐NIHR National Phenome Centre and Imperial BRC Clinical Phenotyping Centre, Division of Computational, Systems and Digestive Medicine, Department of Surgery and Cancer London UK
-
- Jake T. M. Pearce
- The MRC‐NIHR National Phenome Centre and Imperial BRC Clinical Phenotyping Centre, Division of Computational, Systems and Digestive Medicine, Department of Surgery and Cancer London UK
-
- Matthew R. Lewis
- The MRC‐NIHR National Phenome Centre and Imperial BRC Clinical Phenotyping Centre, Division of Computational, Systems and Digestive Medicine, Department of Surgery and Cancer London UK
-
- Elaine Holmes
- The MRC‐NIHR National Phenome Centre and Imperial BRC Clinical Phenotyping Centre, Division of Computational, Systems and Digestive Medicine, Department of Surgery and Cancer London UK
-
- Jeremy K. Nicholson
- The MRC‐NIHR National Phenome Centre and Imperial BRC Clinical Phenotyping Centre, Division of Computational, Systems and Digestive Medicine, Department of Surgery and Cancer London UK
-
- Tricia Tan
- Section of Endocrinology and Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine Imperial College London London UK
-
- Risheka Ratnasabapathy
- Section of Endocrinology and Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine Imperial College London London UK
-
- Ming Hu
- Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine Imperial College London London UK
-
- Gaelle Carrat
- Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine Imperial College London London UK
-
- Lorenzo Piemonti
- Diabetes Research Institute (SR‐DRI), IRCCS San Raffaele Scientific Institute Milan Italy
-
- Marco Bugliani
- Department of Clinical and Experimental Medicine, Islet Cell Laboratory University of Pisa Pisa Italy
-
- Piero Marchetti
- Department of Clinical and Experimental Medicine, Islet Cell Laboratory University of Pisa Pisa Italy
-
- Paul R. Johnson
- Nuffield Department of Surgical Sciences University of Oxford Oxford UK
-
- Stephen J. Hughes
- Nuffield Department of Surgical Sciences University of Oxford Oxford UK
-
- A. M. James Shapiro
- Clinical Islet Laboratory and Clinical Islet Transplant Program University of Alberta Edmonton Canada
-
- Guy A. Rutter
- Section of Cell Biology and Functional Genomics, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine Imperial College London London UK
-
- Waljit S. Dhillo
- Section of Endocrinology and Investigative Medicine, Division of Diabetes, Endocrinology and Metabolism, Department of Medicine Imperial College London London UK
抄録
<jats:sec><jats:title>Aims</jats:title><jats:p>To investigate the effect of kisspeptin on glucose‐stimulated insulin secretion and appetite in humans.</jats:p></jats:sec><jats:sec><jats:title>Materials and methods</jats:title><jats:p>In 15 healthy men (age: 25.2 ± 1.1 years; BMI: 22.3 ± 0.5 kg m<jats:sup>−2</jats:sup>), we compared the effects of 1 nmol kg<jats:sup>−1</jats:sup> h<jats:sup>−1</jats:sup> kisspeptin versus vehicle administration on glucose‐stimulated insulin secretion, metabolites, gut hormones, appetite and food intake. In addition, we assessed the effect of kisspeptin on glucose‐stimulated insulin secretion in vitro in human pancreatic islets and a human β‐cell line (EndoC‐βH1 cells).</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Kisspeptin administration to healthy men enhanced insulin secretion following an intravenous glucose load, and modulated serum metabolites. In keeping with this, kisspeptin increased glucose‐stimulated insulin secretion from human islets and a human pancreatic cell line in vitro. In addition, kisspeptin administration did not alter gut hormones, appetite or food intake in healthy men.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Collectively, these data demonstrate for the first time a beneficial role for kisspeptin in insulin secretion in humans in vivo. This has important implications for our understanding of the links between reproduction and metabolism in humans, as well as for the ongoing translational development of kisspeptin‐based therapies for reproductive and potentially metabolic conditions.</jats:p></jats:sec>
収録刊行物
-
- Diabetes, Obesity and Metabolism
-
Diabetes, Obesity and Metabolism 20 (12), 2800-2810, 2018-08-16
Wiley